Abivax stock sinks 32% as rare malignancy events cloud solid colitis trial data

Investing.com Gold reports: Abivax stock sinks 32% as rare malignancy events cloud solid colitis trial data. Full body text was unavailable at ingest time, so this brief is based on headline context.